Effective treatment of early triple-negative breast cancer in a patient with sickle cell disease through chemotherapy and immune checkpoint inhibitor therapy: The keynote 522 regimen

Hemoglobin SS (Hb SS) disease is a genetic condition leading to acute and chronic complications in all organ systems. There is limited data on cancer treatment outcomes in this population. This case report presents a woman in her mid-40 s with Hb SS disease and early-stage triple-negative breast can...

Celý popis

Uložené v:

Podrobná bibliografia
Vydané v:	Current problems in cancer. Case reports Ročník 20; s. 100393
Hlavní autori:	Froessl, Luise Josefine, Saxon-Filipe, Stevany, Rambally, Siayareh, Syed, Samira
Médium:	Journal Article
Jazyk:	English
Vydavateľské údaje:	Elsevier Inc 01.12.2025
Predmet:	Hematology, Oncology, and Palliative Medicine Immune checkpoint inhibitor therapy Sickle cell disease Triple negative breast cancer Sickle cell disease Immune checkpoint inhibitor therapy Triple negative breast cancer
ISSN:	2666-6219, 2666-6219
On-line prístup:	Získať plný text
Tagy:	Pridať tag Žiadne tagy, Buďte prvý, kto otaguje tento záznam!

Popis
Shrnutí:	Hemoglobin SS (Hb SS) disease is a genetic condition leading to acute and chronic complications in all organ systems. There is limited data on cancer treatment outcomes in this population. This case report presents a woman in her mid-40 s with Hb SS disease and early-stage triple-negative breast cancer (TNBC), treated successfully with the Keynote 522 regimen combining chemotherapy (paclitaxel, carboplatin, doxorubicin and cyclophosphamide) and pembrolizumab. Despite potential risks, the patient tolerated therapy well with no sickle cell crises and only expected moderate side effects. This case demonstrates the feasibility of aggressive cancer treatment in patients with Hb SS disease when managed with close multidisciplinary care, though more research is needed on immunotherapy safety in this group.
ISSN:	2666-6219 2666-6219
DOI:	10.1016/j.cpccr.2025.100393